Impact of suppression of tumorigenicity 14 (ST14)/serine protease 14 (prss14) expression analysis on the prognosis and management of estrogen receptor negative breast cancer

Sauryang Kim, Jae Woong Yang, Chungho Kim, Moon Gyo Kim

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

To elucidate the role of a type II transmembrane serine protease, ST14/Prss14, during breast cancer progression, we utilized publically accessible databases including TCGA, GEO, NCI-60, and CCLE. Survival of breast cancer patients with high ST14/ Prss14 expression is significantly poor in estrogen receptor (ER) negative populations regardless of the ratios of ST14/Prss14 to its inhibitors, SPINT1 or SPINT2. In a clustering of 1085 selected EMT signature genes, ST14/Prss14 is located in the same cluster with CDH3, and closer to post-EMT markers, CDH2, VIM, and FN1 than to the pre-EMT marker, CDH1. Coexpression analyses of known ST14/Prss14 substrates and transcription factors revealed context dependent action. In cell lines, paradoxically, ST14/Prss14 expression is higher in the ER positive group and located closer to CDH1 in clustering. This apparent contradiction is not likely due to ST14/Prss14 expression in a cancer microenvironment, nor due to negative regulation by ER. Genes consistently coexpressed with ST14/Prss14 include transcription factors, ELF5, GRHL1, VGLL1, suggesting currently unknown mechanisms for regulation. Here, we report that ST14/Prss14 is an emerging therapeutic target for breast cancer where HER2 is not applicable. In addition we suggest that careful conclusions should be drawn not exclusively from the cell line studies for target development.

Original languageEnglish
Pages (from-to)34643-34663
Number of pages21
JournalOncotarget
Volume7
Issue number23
DOIs
Publication statusPublished - 2016 Jun 7

Fingerprint

Serine Proteases
Estrogen Receptors
Breast Neoplasms
Cluster Analysis
Transcription Factors
Cell Line
Tumor Microenvironment
Genes
Databases
Survival
Population
Therapeutics

Keywords

  • Breast cancer
  • Epithelial mesenchymal transition (EMT)
  • Epithin
  • Prss14
  • ST14

ASJC Scopus subject areas

  • Oncology

Cite this

Impact of suppression of tumorigenicity 14 (ST14)/serine protease 14 (prss14) expression analysis on the prognosis and management of estrogen receptor negative breast cancer. / Kim, Sauryang; Yang, Jae Woong; Kim, Chungho; Kim, Moon Gyo.

In: Oncotarget, Vol. 7, No. 23, 07.06.2016, p. 34643-34663.

Research output: Contribution to journalArticle

@article{1f47456587c54f5bb843cfba5de58210,
title = "Impact of suppression of tumorigenicity 14 (ST14)/serine protease 14 (prss14) expression analysis on the prognosis and management of estrogen receptor negative breast cancer",
abstract = "To elucidate the role of a type II transmembrane serine protease, ST14/Prss14, during breast cancer progression, we utilized publically accessible databases including TCGA, GEO, NCI-60, and CCLE. Survival of breast cancer patients with high ST14/ Prss14 expression is significantly poor in estrogen receptor (ER) negative populations regardless of the ratios of ST14/Prss14 to its inhibitors, SPINT1 or SPINT2. In a clustering of 1085 selected EMT signature genes, ST14/Prss14 is located in the same cluster with CDH3, and closer to post-EMT markers, CDH2, VIM, and FN1 than to the pre-EMT marker, CDH1. Coexpression analyses of known ST14/Prss14 substrates and transcription factors revealed context dependent action. In cell lines, paradoxically, ST14/Prss14 expression is higher in the ER positive group and located closer to CDH1 in clustering. This apparent contradiction is not likely due to ST14/Prss14 expression in a cancer microenvironment, nor due to negative regulation by ER. Genes consistently coexpressed with ST14/Prss14 include transcription factors, ELF5, GRHL1, VGLL1, suggesting currently unknown mechanisms for regulation. Here, we report that ST14/Prss14 is an emerging therapeutic target for breast cancer where HER2 is not applicable. In addition we suggest that careful conclusions should be drawn not exclusively from the cell line studies for target development.",
keywords = "Breast cancer, Epithelial mesenchymal transition (EMT), Epithin, Prss14, ST14",
author = "Sauryang Kim and Yang, {Jae Woong} and Chungho Kim and Kim, {Moon Gyo}",
year = "2016",
month = "6",
day = "7",
doi = "10.18632/oncotarget.9155",
language = "English",
volume = "7",
pages = "34643--34663",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "23",

}

TY - JOUR

T1 - Impact of suppression of tumorigenicity 14 (ST14)/serine protease 14 (prss14) expression analysis on the prognosis and management of estrogen receptor negative breast cancer

AU - Kim, Sauryang

AU - Yang, Jae Woong

AU - Kim, Chungho

AU - Kim, Moon Gyo

PY - 2016/6/7

Y1 - 2016/6/7

N2 - To elucidate the role of a type II transmembrane serine protease, ST14/Prss14, during breast cancer progression, we utilized publically accessible databases including TCGA, GEO, NCI-60, and CCLE. Survival of breast cancer patients with high ST14/ Prss14 expression is significantly poor in estrogen receptor (ER) negative populations regardless of the ratios of ST14/Prss14 to its inhibitors, SPINT1 or SPINT2. In a clustering of 1085 selected EMT signature genes, ST14/Prss14 is located in the same cluster with CDH3, and closer to post-EMT markers, CDH2, VIM, and FN1 than to the pre-EMT marker, CDH1. Coexpression analyses of known ST14/Prss14 substrates and transcription factors revealed context dependent action. In cell lines, paradoxically, ST14/Prss14 expression is higher in the ER positive group and located closer to CDH1 in clustering. This apparent contradiction is not likely due to ST14/Prss14 expression in a cancer microenvironment, nor due to negative regulation by ER. Genes consistently coexpressed with ST14/Prss14 include transcription factors, ELF5, GRHL1, VGLL1, suggesting currently unknown mechanisms for regulation. Here, we report that ST14/Prss14 is an emerging therapeutic target for breast cancer where HER2 is not applicable. In addition we suggest that careful conclusions should be drawn not exclusively from the cell line studies for target development.

AB - To elucidate the role of a type II transmembrane serine protease, ST14/Prss14, during breast cancer progression, we utilized publically accessible databases including TCGA, GEO, NCI-60, and CCLE. Survival of breast cancer patients with high ST14/ Prss14 expression is significantly poor in estrogen receptor (ER) negative populations regardless of the ratios of ST14/Prss14 to its inhibitors, SPINT1 or SPINT2. In a clustering of 1085 selected EMT signature genes, ST14/Prss14 is located in the same cluster with CDH3, and closer to post-EMT markers, CDH2, VIM, and FN1 than to the pre-EMT marker, CDH1. Coexpression analyses of known ST14/Prss14 substrates and transcription factors revealed context dependent action. In cell lines, paradoxically, ST14/Prss14 expression is higher in the ER positive group and located closer to CDH1 in clustering. This apparent contradiction is not likely due to ST14/Prss14 expression in a cancer microenvironment, nor due to negative regulation by ER. Genes consistently coexpressed with ST14/Prss14 include transcription factors, ELF5, GRHL1, VGLL1, suggesting currently unknown mechanisms for regulation. Here, we report that ST14/Prss14 is an emerging therapeutic target for breast cancer where HER2 is not applicable. In addition we suggest that careful conclusions should be drawn not exclusively from the cell line studies for target development.

KW - Breast cancer

KW - Epithelial mesenchymal transition (EMT)

KW - Epithin

KW - Prss14

KW - ST14

UR - http://www.scopus.com/inward/record.url?scp=84973644249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973644249&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.9155

DO - 10.18632/oncotarget.9155

M3 - Article

C2 - 27167193

AN - SCOPUS:84973644249

VL - 7

SP - 34643

EP - 34663

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 23

ER -